Subscribe To
Theratechnologies to present preliminary safety and efficacy data from phase 1 trial of sudocetaxel zendusortide in heavily pretreated cancer patients at asco 2023
MONTREAL, May 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharma...
May 25, 2023, 5:31 pm
Shattuck labs to present complete dose-escalation data from phase 1a monotherapy clinical trial of sl-172154 in platinum-resistant ovarian cancer (proc) at the american society of clinical oncology (a
- SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharm...
May 25, 2023, 5:15 pm
Shattuck labs to present complete dose-escalation data from phase 1a monotherapy clinical trial of sl-172154 in platinum-resistant ovarian cancer (proc) at the american society of clinical oncology (a
- SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharm...
May 25, 2023, 5:15 pm
Leap therapeutics to present updated data from part a of the distinguish study of dkn-01 plus tislelizumab and chemotherapy in gastric cancer patients at the 2023 asco annual meeting
19.5 months median OS in the overall first-line patient population, exceeding current benchmarks Long-term follow-up identifies additional patient wit...
May 25, 2023, 5:10 pm
Nkgen announces poster presentation at the 2023 american society of clinical oncology (asco) annual meeting
SANTA ANA, Calif., May 25, 2023 (GLOBE NEWSWIRE) — NKGen Biotech Inc. (“NKGen”), a clinical-stage biotechnology company focused on the developme...
May 25, 2023, 5:05 pm
Sellas life sciences to present phase 3 regal trial in progress poster at 2023 asco annual meeting
NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical b...
May 25, 2023, 5:05 pm
Molecular partners to present positive data from ongoing phase 1 trial of mp0317 (fap x cd40) monotherapy in patients with advanced solid tumors at the 2023 asco annual meeting
MP0317 demonstrates tumor-localized CD40 activation in tumor biopsies through target occupancy and immune cell activation...
May 25, 2023, 5:01 pm
Bristol myers squibb to present first results at asco and eha from phase 3 commands study of reblozyl® (luspatercept-aamt) in first-line treatment of anemia in adults with lower-risk myelodysplastic s
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS to Present First Results at ASCO & EHA from phase ...
May 25, 2023, 5:00 pm
Bristol myers squibb to present first results at asco and eha from phase 3 commands study of reblozyl® (luspatercept-aamt) in first-line treatment of anemia in adults with lower-risk myelodysplastic s
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS to Present First Results at ASCO & EHA from phase ...
May 25, 2023, 5:00 pm
Mirati's (mrtx) sitravatinib fails lung cancer study, stock down 8%
Mirati Therapeutics' (MRTX) phase III study evaluating sitravatinib as a combination therapy in certain...
May 25, 2023, 3:47 pm
Why shares of annexon are plummeting thursday
Annexon still plans a phase 3 study for therapy ANX007. The first therapy to treat geographic atrophy (...
May 25, 2023, 11:52 am
Angle technology to be used in cancer clinical trial
ANGLE PLC (AIM:AGL, OTCQX:ANPCY), a pioneer of liquid biopsy technology, announced a significant contract win with Artios Pharma. Under the deal ANG...
May 25, 2023, 2:36 am
Usd/chf price analysis: enters into a markup phase after an accumulation breakout
USD/CHF has entered into a markup phase after delivering a breakout of the Wyckoff Accumulation pattern...
May 25, 2023, 12:29 am
Lattice semiconductor enters new growth phase, targets higher margins
Lattice Semiconductor has been on a five-year transition and is now entering its next phase of growth w...
May 24, 2023, 10:06 pm
Protagonist therapeutics: all quiet heading into an important h2 2023
Protagonist continues to quietly progress its pipeline, relying mainly on the polycythemia vera story to drive its business efforts. An ongoing ...
May 24, 2023, 5:33 pm
Fulcrum therapeutics: fshd steadily advancing in phase 3, optionality with scd
Crisis of confidence in prior management (related to full clinical hold in February for FTX-6058 in SCD) led to currently cheap valuation. New CEO (ap...
May 24, 2023, 2:15 pm
Immunovant could be poised for a breakout in h2 2023
Rating: Buy-rating maintained based on IMVT-1402's unique potential and impending phase 1 catalyst in 2...
May 24, 2023, 1:14 pm
Here's why hepion pharma (hepa) is up more than 80% in two days
Hepion Pharmaceuticals' (HEPA) lead pipeline candidate, rencofilstat, demonstrates improvements in physiologic liver function and key NASH biomarkers ...
May 24, 2023, 1:13 pm
Pyxis oncology to acquire apexigen
Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate (ADC) development Commercially and clinically validated APXiMAB platform for antibod...
May 24, 2023, 10:45 am
Spc nickel finds 'one of the best intersections so far' at west graham nickel-copper project
SPC Nickel Corp (TSX-V:SPC, OTC:SPCNF) has announced new assay results from phase 1 of the resource def...
May 24, 2023, 9:05 am